Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significantly greater reductions in HbA1c and body weight compared to semaglutide 1 mg and basal insulins in adults with type 2 diabetes.
Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with type 2 diabetes, outperforming other common treatments like semaglutide and basal insulins in clinical trials.
StrongSupportsHIGH confidence
In SUPRASS-2, these reductions were greater than with the GLP-1 receptor agonist semaglutide 1 mg... Tirzepatide was associated with marked reductions of glycated haemoglobin (-1.87 to -2.59%) and body weight (-6.2 to -12.9 kg).
Why this rating
Phase 3 randomized controlled trials (SURPASS 1-5).
Source
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block et al. · Diabetes Obesity and Metabolism · 2022
DOI 10.1111/dom.14831
narrative_review · n=6263Cited 108×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →